Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data

被引：0
作者：
Ani John
Baiyu Yang
Roma Shah
机构：
[1] Roche Diagnostics,
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Adherence; Biomarker; First-line treatment; Guidelines; Non-small cell lung cancer; Precision medicine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1552 / 1566
页数：14
相关论文
共 50 条
  • [31] Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer
    Piacentini, Paolo
    Greco, Filippo
    Mercanti, Anna
    Trolese, Anna Rita
    Durante, Emilia
    Moratello, Giacomo
    Tognetto, Michele
    Furini, Lara
    Giuliani, Jacopo
    Bonetti, Andrea
    TUMORI JOURNAL, 2013, 99 (06): : 650 - 655
  • [32] Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer
    Gori, Bruno
    Ricciardi, Serena
    Del Signore, Ester
    Fulvi, Alberto
    de Marinis, Filippo
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 : S55 - S60
  • [33] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Tania Losanno
    Cesare Gridelli
    Current Oncology Reports, 2021, 23
  • [34] Real-World Treatment Patterns and Outcomes for Patients With Advanced Non-Small Cell Lung Cancer in Greece
    Kokkotou, E.
    Charpidou, A.
    Papaspiliou, A.
    Stournara, L.
    Grammatikou, V.
    Ejzykowicz, F.
    Syrigos, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S319 - S319
  • [35] Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancer
    Wang, Lin
    Liu, Ting
    Lin, Xihan
    Zhang, Yu
    Shi, Luwen
    You, Ruxu
    Liu, Jinyu
    IMMUNOTHERAPY, 2024, 16 (20-22) : 1217 - 1226
  • [36] Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer
    Xing, Puyuan
    Mu, Yuxin
    Wang, Yan
    Hao, Xuezhi
    Zhu, Yixiang
    Hu, Xingsheng
    Wang, Hongyu
    Liu, Peng
    Lin, Lin
    Wang, Zhijie
    Li, Junling
    THORACIC CANCER, 2018, 9 (07) : 805 - 813
  • [37] First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer
    Lange, T
    Müller-Tidow, C
    Serve, H
    Hoffknecht, P
    Berdel, WE
    Thomas, M
    ONCOLOGY REPORTS, 2005, 14 (06) : 1539 - 1542
  • [38] Real-World Maintenance Treatment Patterns Among Patients with Advanced Non-Small Cell Lung Cancer
    Manasee V. Shah
    Caitlyn T. Solem
    Kelly F. Bell
    Amine Aziez
    Xuezheng Sun
    Mandy Du
    Ella X. Du
    Hongbo Yang
    Hongjue Wang
    Qi Hua
    Umit Tapan
    Advances in Therapy, 2025, 42 (6) : 2782 - 2796
  • [39] Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer
    Betts, Keith A.
    Gao, Sophie
    Ray, Saurabh
    Schoenfeld, Adam J.
    FUTURE ONCOLOGY, 2024, 20 (13) : 851 - 862
  • [40] The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Wang, Fen
    Jin, Feng
    Cheng, Boran
    Zhang, Yue
    Zhou, Qing
    Wang, Shubin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (07) : 1721 - 1735
12345